GW3965 HCl

For research use only. Not for use in humans.

目录号:S2630

GW3965 HCl Chemical Structure

CAS No. 405911-17-3

GW3965 HCl是一种有效的,选择性LXR激动剂,作用于hLXRα和hLXRβ,无细胞试验中EC50分别为190和30 nM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1966.57 现货
RMB 790.51 现货
RMB 4654.57 现货
RMB 9746.1 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的GW3965 HCl发表文献30篇:

产品安全说明书

Liver X Receptor抑制剂选择性比较

生物活性

产品描述 GW3965 HCl是一种有效的,选择性LXR激动剂,作用于hLXRα和hLXRβ,无细胞试验中EC50分别为190和30 nM。
靶点
hLXRβ [1]
(Cell-free assay)
LXRα/SRC1 LiSA [1]
(Cell-free assay)
hLXRα [1]
(Cell-free assay)
30 nM(EC50) 125 nM(EC50) 190 nM(EC50)
体外研究

GW3965使类固醇受体共激活因子1聚集到LXRα,在无细胞配体检测试验中,EC50 为125 nM。[1] GW3965对hLXRα 和 hLXRβ表现出有效的拮抗活性,在细胞试验中EC50分别为190 nM 和30 nM。此外,GW3965也对其他核受体表现出优良的选择性。[1]在人胰岛中,GW3965 (1 μM)降低选定促炎性细胞因子,包括IL-8,单核细胞趋化蛋白-1和组织因子的表达。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 M{DmZlExKHWP M{S0U|IxKGi{cx?= MlzSRYN1cX[jdHnvckBw\iCqdX3hckBNYFKjbIDoZUBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJINwNWW6cILld5NqdmdiaIXtZY4hWliUYXzwbIEh[XRiMUCgeW0h[W[2ZYKgNlAhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NVzxXZQ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwNFY6ODlpPkK4NFA3QTB7PD;hQi=>
HEK293 NXLwTlNHOTBidV2= Mo\vNlAhcHK| MXrBZ5RqfmG2aX;uJI9nKHKjdDDMXHJj\XSjIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiY3:t[ZhxemW|c3nu[{BpfW2jbjDSXHJidHCqYTDheEAyOCC3TTDh[pRmeiB{MDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5 M13jXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEC2PVA6Lz5{OECwOlkxQTxxYU6=
THP1 MmjQSpVv[3Srb36gZZN{[Xl? NVXGXZg{UW6mdXP0bY9vKG:oIHPoc4xme3Sncn;sJIVn\my3eDDpckBVUFBzIHPlcIx{NCCHQ{WwJF0hOC5yMTFOwG0v NYr0c3NyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1PFc2PzNpPkG3OVg4PTd|PD;hQi=>
THP1 MlzJSpVv[3Srb36gZZN{[Xl? MlLRNVghcHK| MmXhTY5lfWO2aX;uJI9nKGOqb3zld5Rmem:uIHXm[ox2gCCrbjDUTHAyKGOnbHzzJIFnfGW{IEG4JIhzeyxiRVO1NEA:KDBwMEGg{txONg>? NGrLcpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{SxOlUzOSd-MUe0NVY2OjF:L3G+
COS7 MmDWSpVv[3Srb36gZZN{[Xl? M2rNeVE3KGi{cx?= M1L3PWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gUHhT[mW2YTDy[YNmeHSxcjD0doFve2[nY4Tl[EBqdiCFT2O3JINmdGy|IHHmeIVzKDF4IHjyd{BjgSC{ZYDvdpRmeiC2cnHud4FkfGm4YYTpc44h[XO|YYmsJGVEPTBiPTCwMlAyPSEQvF2u NE\LUVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W4O|U4Oyd-MUe1PFc2PzN:L3G+
COS7 NYjvVlZFTnWwY4Tpc44h[XO|YYm= NYrzd3FwSWO2aY\heIlwdiCxZjDMXHJj\XSjIHPvMZRz[W6|ZnXjeIVlKGmwIFPPV|ch[2WubIOge4l1cCCUWGLhcJBp[SCkeTDy[ZBwenSncjD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUCgQUAxNjBzNTFOwG0v MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzNkWyNUc,OTd2MU[1NlE9N2F-
THP1 M1;LZ2FvfGmrbn\sZY1u[XSxcomgZZN{[Xl? MlfNOkBpenN? MWjBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hXEiSMTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJGlNPiCycn;keYN1cW:wIHHmeIVzKDZiaILzJIJ6KEWOSWPBMEBKSzVyIE2gNE4xOiEQvF2u MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDhyMEe2O{c,OTh6MEC3Olc9N2F-
THP1 M3\sfmZ2dmO2aX;uJIF{e2G7 NX;5SYY4SWexbnnzeEBi[3Srdnn0fUBifCCJQVytcIlvc2WmIHj1cYFvKEy[UnLleIEh\XiycnXzd4VlKGmwIGTIVFEh[2WubIOgZZN{\XO|ZXSgZZMhe3SrbYXsZZRqd25ib3[gZ48u[WO2aY\heI9zKHKnY4L1bZRu\W62IHL5JGZTTVRiYYPzZZktKEWFNUCgQUAxNjB{NzFOwG0v NGDtZog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[2OVg6Pyd-MUe2OlU5QTd:L3G+
RAW264.7 NViySJN2TnWwY4Tpc44h[XO|YYm= MoL5NlQhcHK| NYHOc|BjUW6mdXP0bY9vKG:oIGuzTH1kcG:uZYP0[ZJwdCCnZn\seZghcW5ibX;1d4UhWkGZMk[0Mlch[2WubIOgcI9i\GWmIIfpeIgh[WOndInsZZRm\C2ORFygZYZ1\XJiMkSgbJJ{NCCHQ{WwJF0hOC5yMkmg{txONg>? M4P6dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G3N|A1Lz5zOUexO|MxPDxxYU6=
THP1 MYTGeY5kfGmxbjDhd5NigQ>? MlnuV5RqdXWuYYTpc44hd2ZiW{PIYYNpd2ync4Tldo9tKGWoZnz1fEBqdiCqdX3hckBVUFBzIH\vZY0h[2WubIOgcI9i\GWmIIfpeIgh[WNvTFTMMEBGSzVyIE2gNE4xOzFizszNMi=> NXzNbJA1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5O|MzQDhpPkG4PVc{Ojh6PD;hQi=>
CV1 MVTGeY5kfGmxbjDhd5NigQ>? NEGzRZJCdnSjZ3;ubZN1KGGldHn2bZR6KGG2IFzYVoJmfGFibHnnZY5lKGKrbnTpcoch\G:vYXnuJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWFE{OTdvaX7keYNm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkhcW5iYX\ybYNidiCpcnXlckBud26tZYmgR3YyKGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghT2GuND3TVmMyKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKgZZN{[XluIFnDOVAhRSByLkCzPVgyKM7:TT6= MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB|NEWxNFIoRjJyM{S1NVAzRC:jPh?=
THP1 MXTGeY5kfGmxbjDhd5NigQ>? M1P6[mFod26rc4SgZYN1cX[rdImgZZQhT0GOLXzpcotm\CCqdX3hckBNYFKjbIDoZUBmgHC{ZYPz[YQhcW5iVFjQNUBk\WyuczDhd5Nme3OnZDDhd{B{fGmvdXzheIlwdiCxZjDjc4FkfGm4YYTvdkBz\WO{dXn0cYVvfCCkeTDGVmVVKGG|c3H5MEBGSzVyIE2gNE4xQTdizszNMi=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ4NUi5O{c,OTd4NkW4PVc9N2F-
CV1 MoTDSpVv[3Srb36gZZN{[Xl? M4rOOmFvfGGpb37pd5Qh[WO2aY\peJkh[XRiTGjSZYxxcGFibHnnZY5lKGKrbnTpcoch\G:vYXnuJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gWFE{OTdvaX7keYNm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkhcW5iYX\ybYNidiCpcnXlckBud26tZYmgR3YyKGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghT2GuND3TVmMyKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKgZZN{[XluIFnDOVAhRSByLkGg{txONg>? M1uwclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{S1NVAzLz5{MEO0OVExOjxxYU6=
SH-SY5Y M{ixSmZ2dmO2aX;uJIF{e2G7 MXeyOEBpenN? NYO5eGdrSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBNYFKkZYThJIV5eHKnc4Pl[EBqdiCqdX3hckBUUC2VWUXZJINmdGy|IHPvMZRz[W6|ZnXjeIVlKHerdHigS4FtPC2OQlSgZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvOTNizszNMi=> MkD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{NkS0PFEoRjF7Mk[0OFgyRC:jPh?=
HepG2 M33jeGZ2dmO2aX;uJIF{e2G7 M3Lve2Vn\mWldDDvckBUWkWEUEHjJIdmdmViZYjwdoV{e2mxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{whTUN3MDC9JFAvOjFizszNMi=> M4CxS|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUezNlg5Lz5zOEm3N|I5QDxxYU6=
HuH7 Mmi5SpVv[3Srb36gZZN{[Xl? Mlz6RYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDy[YNwdWKrbnHueEBNYFKkZYThJIxq\2GwZDDibY5lcW6pIHTvcYFqdiCrbjDoeY1idiCKdVi3JINmdGy|IHPvMZRz[W6|ZnXjeIVlKHerdHig[pV{\WRiR3HsOE1FSkRiYomgeJJidnOjY4TpeoF1cW:wIHHzd4F6NCCHQ{WwJF0hOC5|MTFOwG0v NV6zcnVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5O|MzQDhpPkG4PVc{Ojh6PD;hQi=>
SH-SY5Y NXH3bHB1TnWwY4Tpc44h[XO|YYm= NFmyWIYzPCCqcoO= M17FWGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gUHhT[WyyaHGg[ZhxemW|c3XkJIlvKGi3bXHuJHNJNVO\NWmgZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDHZYw1NUyERDDh[pRmeiB{NDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBGSzVyIE2gNE4{OSEQvF2u MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ4NES4NUc,OTl{NkS0PFE9N2F-
CHO MXXGeY5kfGmxbjDhd5NigQ>? M13JdGFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gUHhTKGKndHGgdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyCkeTDy[ZBwenSncjDhd5NigSxiRVO1NEA:KDBwNEGg{txONg>? MmDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyM{SxNVkoRjF5MEO0NVE6RC:jPh?=
CHOK1 M2LEfWZ2dmO2aX;uJIF{e2G7 MYmyOEBpenN? NYP6XlVvSWexbnnzeEBi[3Srdnn0fUBifCCJYXy0MZRi\2enZDDMXHJj\XSjIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGNJV0tzIHPlcIx{KGGodHXyJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkSyJO69VS5? NIDGOGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[3O|Y3PCd-MkW2O|c3PjR:L3G+
THP1 MW\GeY5kfGmxbjDhd5NigQ>? NWG4fo0zTW[oZXP0JI9vKEGEQ1GxJIdmdmViZYjwdoV{e2mxbjDpckBpfW2jbjDkbYZn\XKnboTpZZRm\CCWSGCxJINmdGy|LDDFR|UxKD1iMD60N|Qh|ryPLh?= MkPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7N{OyPFgoRjF6OUezNlg5RC:jPh?=
CV1 NX3VU2FiTnWwY4Tpc44h[XO|YYm= MX7B[49vcXO2IHHjeIl3cXS7IHH0JGxZWmKndHGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvNW2nZHnheIVlKHS{YX7zZ5JqeHSrb37hcEBi[3Srdnn0fUBqdiCjZoLpZ4FvKGe{ZXXuJI1wdmuneTDDWlEh[2WubIOgZ48ufHKjboPm[YN1\WRid3n0bEBI[Wx2LWPSR|Eh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDhd5NigSxiRVO1NEA:KDBwNUCxNVkh|ryPLh?= MlXrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB|NEWxNFIoRjJyM{S1NVAzRC:jPh?=
HuH7 NFTIN49HfW6ldHnvckBie3OjeR?= NEi5blVC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJJJm[2:vYnnuZY51KEy[UnHsdIhiKGyrZ3Hu[EBjcW6maX7nJIRwdWGrbjDpckBpfW2jbjDIeWg4KGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIgh\nW|ZXSgS4FtPC2GQlSgZpkhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR|UxKD1iMD62OkDPxE1w MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl5M{K4PEc,OTh7N{OyPFg9N2F-
CV1 NH\XSFhHfW6ldHnvckBie3OjeR?= M4XEZmFod26rc4SgZYN1cX[rdImgZZQhVFiUYXzwbIEhdGmpYX7kJIJqdmSrbneg[I9u[WmwLX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEXjFiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCJYXy0MXNTSzFiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygSWM2OCB;IECuO|k1OzNizszNMi=> NFvWbYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OVExOid-MkCzOFUyODJ:L3G+
CHOK1 NGHLNFlHfW6ldHnvckBie3OjeR?= Mn63NlQhcHK| NVnZT2NbSWexbnnzeEBi[3Srdnn0fUBifCCJYXy0MZRi\2enZDDMXHJidHCqYTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBEUE:NMTDj[YxteyCjZoTldkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR|UxKD1iMT6zJO69VS5? Ml\0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4N{e2OlQoRjJ3Nke3OlY1RC:jPh?=
HepG2 M17FXWZ2dmO2aX;uJIF{e2G7 NG\3TnBG\m[nY4Sgc44hfHKrZ3z5Z4VzcWSnIHHjZ5VufWyjdHnvckBqdiCqdX3hckBJ\XCJMjDj[YxteyxiRVO1NEA:KDJwMECyJO69VS5? MonPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7N{OyPFgoRjF6OUezNlg5RC:jPh?=
HepG2 NGXld|BHfW6ldHnvckBie3OjeR?= M1\2RlUxOCCwTR?= MmTZTY5pcWKrdHnvckBw\iB{LTizMUg{NShqMj3jbIxwem9vMz2oeJJq\my3b4LvcYV1cHmuKXLlcpp6dClqMjyyMYRqeGinbons[ZRpgWxrYX3pco8qeHKxcH;4fUlxcGWweXypZYNmfGmlIHHjbYQucW6mdXPl[EB{emWkcEHjJI1TVkFiZYjwdoV{e2mxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{BifCB3MECgcm0> NYmycYZmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4NFA4PjdpPkG4PFAxPzZ5PD;hQi=>
HepG2 MonsSpVv[3Srb36gZZN{[Xl? NWnXT5V7PTByIH7N M37sRWlvcGmkaYTpc44hd2ZiMj2oN{0pOy1qKEKtZ4htd3KxLUOtLJRzcW[udX;yc41mfGi7bDni[Y57gWxrKEKsNk1lcXCqZX75cIV1cHmuKXHtbY5wMXC{b4DvfJkqeGinbonsLYFk\XSrYzDhZ4llNWmwZIXj[YQh\mG|IH3SUmEh\XiycnXzd4lwdiCrbjDoeY1idiCKZYDHNkBk\WyuczDheEA2ODBibl2= NEDnPIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEiwNFc3Pyd-MUi4NFA4Pjd:L3G+
RAW264.7 MU\GeY5kfGmxbjDhd5NigQ>? NGLoVYQyKHWP NWPqNVlQWmWmdXP0bY9vKG:oIFzQV{1{fGmvdXzheIVlKGmQT2Og[4Vv\SCneIDy[ZN{cW:wIHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{KGW6cILld5NqdmdiTGjSZYxxcGFiYYSgNUB2VSCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> MnLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MEC3OlcoRjF6OECwO|Y4RC:jPh?=
RAW264.7 MkPISpVv[3Srb36gZZN{[Xl? M4\GdVEhfU1? MkfITY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBvfWOuZXHyJINwNXKncILld5NweiC{ZXzlZZNmKG[{b32gbW5QWyCycn;tc5RmeiCrbjDtc5V{\SCUQWeyOlQvPyClZXzsd{BifCBzIIXNJIJ6KFKWLWDDVi=> NFvjXIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEiwNFc3Pyd-MUi4NFA4Pjd:L3G+
HeLa MY\GeY5kfGmxbjDhd5NigQ>? M3XIZlEhfU1? NGqxZpNKdmS3Y4Tpc44hd2ZiTGjSZoV1[SCVVV3PfYxifGmxbjDifUBUXU2RMjDpckBpfW2jbjDI[WxiKGOnbHzzJIF1KDFidV2gZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MmT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MEC3OlcoRjF6OECwO|Y4RC:jPh?=
HeLa MnriSpVv[3Srb36gZZN{[Xl? M{XyNVEhfU1? M17GfGlv\HWldHnvckBw\iCOWGLi[ZRiKFOXTV;5cIF1cW:wIHL5JHNWVU9|IHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOSC3TTDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? NXPjPHVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4NFA4PjdpPkG4PFAxPzZ5PD;hQi=>
HeLa M{XOWWZ2dmO2aX;uJIF{e2G7 MmHGNUB2VQ>? MUHJcoR2[3Srb36gc4YhVFiUYXzwbIEhW1WPT4nsZZRqd25iYomgV3VOVzNiaX6gbJVu[W5iSHXMZUBk\WyuczDheEAyKHWPIHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MlnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MEC3OlcoRjF6OECwO|Y4RC:jPh?=
DAOY M3PwOZFJXFNiYYPzZZk> MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? NI[we3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SJ-GBM2 NHfqPXFyUFSVIHHzd4F6 Mor0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= Ml;aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 M4j6O5FJXFNiYYPzZZk> M3\rZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NHTQd4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NFi3WlByUFSVIHHzd4F6 NH3mZZVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NH\hZZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 M3rDXJFJXFNiYYPzZZk> MVzxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? M1LrV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 MljVdWhVWyCjc4PhfS=> MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH M1TZOpFJXFNiYYPzZZk> M2nDTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz NWnKUFZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NX\QbnNNeUiWUzDhd5NigQ>? MkG4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy| MnXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 M3nlRZFJXFNiYYPzZZk> MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| M1;CO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NI\DdnVyUFSVIHHzd4F6 NY\vcphEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| NX;ySIJlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) M2fYPJFJXFNiYYPzZZk> MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVUdiNkOgLFYuXEdiUjmgZ4VtdHN? NHrLeIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 NH;5bIlyUFSVIHHzd4F6 M4[1UZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy| M4ntRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 NYTMVFZweUiWUzDhd5NigQ>? MX\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NGWzVo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Skp2 / pEGFR / EGFR / pERK / ERK ; 

PubMed: 25184494     


GW3965 treatment downregulates SKP2 and EGFR protein levels in BxPC-3 and MIA-PaCa-2 cells. Downregulation of EGFR was concomitant with a downregulation of its own phosphorylation in BxPC-3 and MIA-PaCa-2 at 5 uM GW 3965. ERK1/2 and its phosphorylation were not statistically different in any of the cell lines.

LXRα / LXRβ / ABCA1 / ABCG1; 

PubMed: 11604492     


Differentiated THP-1 macrophages were incubated for 48 h in RPMI medium plus 10% LPDS, Oxysterols [20(S)HC, 22(R)HC, or 22(S)HC, 2.0 μg/ml], synthetic LXR ligand (GW3965 or T1317, 0.1 to 10.0 μM), or RXR ligand (LG268, 50 nM).

25184494 11604492
Immunofluorescence
LAMP-1 / LDLR; 

PubMed: 23382078     


HeLa cells were cultured in 10% LPDS medium for 8 h and then treated with GW3965 (1 μM) for the indicated times. Cells were immunostained with LDLR and LAMP-1 antibodies. Nuclei were counterstained with DAPI (blue). Representative confocal images are shown. T, time; O/N, overnight.

pRelA ; 

PubMed: 26635040     


Freshly isolated PDC (plasmacytoid dendritic cells) were treated for 24 h with 1 mM of GW3965 (GW), followed by TLR7 ligand, R848 (1 mg/mL) for 45 min. Phosphorylation of the NF-κB p65 (pRelA) subunit and its cellular localization were evaluated by confocal microscopy analysis. Results from a representative experiment out of 3 using PDC from 3 different donors.

23382078 26635040
Growth inhibition assay
Cell viability; 

PubMed: 25184494     


A, B, C, PDAC cells (BxPC-3, Mia-PaCa-2, and PANC-1 cell lines, respectively) show dose-dependent decreases in cell proliferation upon treatment with increasing GW3965 concentrations. EC50 calculations indicate that BxPC-3 and Mia-PaCa-2 cells are more sensitive to ligand treatment than PANC-1 cells. 

25184494
体内研究 在小鼠体内,GW3965在10 mg/kg剂量下使ABCA1表达上调8倍,并使循环水平提高30%,Cmax为12.7 μg/mL ,t1/2为2小时。[1] 在LDLR−/−和apoE−/−小鼠体内,GW3965 (10mg/kg)诱导ABCA1 和ABCG1表达,并表现出有效的抗动脉粥样硬化活性。[2]在雄性sprague-dawley大鼠体内,GW3965降低Ang II介导的血压增加,并减少血管Ang II受体基因表达。[3]在恶性胶质瘤小鼠模型中,GW3965导致LDLR降解,增加ABCA1胆固醇外排转运体的表达,从而有效促进肿瘤细胞死亡。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[1]
- 合并
  • Animal Models: C57BL/6 小鼠
  • Dosages: ≤10 mg/kg
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 16 mg/mL warmed (25.86 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 618.51
化学式

C33H31ClF3NO3.HCl

CAS号 405911-17-3
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to formulate the compound for mouse in vivo experiment?

  • 回答:

    S2630 GW3965 HCl can be dissolved in 2% DMSO/30% PEG 300/dd H2O at 10 mg/mL as a homogeneous suspension. This vehicle is suitable for oral gavage to mice.

相关Liver X Receptor产品

Tags: 购买GW3965 HCl | GW3965 HCl供应商 | 采购GW3965 HCl | GW3965 HCl价格 | GW3965 HCl生产 | 订购GW3965 HCl | GW3965 HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID